Adjuvant treatment of early-stage melanoma by local i.d. administration of low-dose CpG-B and GM-CSF increases recurrence-free survival: long-term follow-up of three randomized clinical trials

Ítems similars

• Pre-operative intradermal administration of CpG-B ± GM-CSF in stage I-III melanoma patients arms the sentinel lymph node: evidence for reduced tumor spread
  per: van den Hout, Mari F, et al.
  Publicat: (2013)
• In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma
  per: Koster, Bas D., et al.
  Publicat: (2019)
• Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node
  per: van den Hout, Mari F. C. M., et al.
  Publicat: (2016)
• T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A(+)CD141(+) cDC1 and CD14(+) antigen-presenting cell recruitment
  per: Koster, Bas D, et al.
  Publicat: (2021)
• Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial
  per: Koster, Bas D., et al.
  Publicat: (2019)